Acasti Pharma and CordenPharma Announce Large-Scale Production of CaPre with Continuous Manufacturing

News
Article

Acasti Pharma and CDMO CordenPharma designed and implemented a continuous process for purifying raw krill oil for production of omega-3 phospholipid.

Acasti Pharma achieved the milestone of manufacturing the first cGMP batches of CaPre, Acasti’s omega-3 pharmaceutical product candidate, produced with a proprietary continuous manufacturing process developed in partnership with CordenPharma, the companies announced in a press release on June 1, 2017. The process was jointly designed and implemented by the Acasti and CordenPharma technical teams and engineers at the CordenPharma Chenôve facility in Dijon, France.

This continuous manufacturing process allows an increased throughput and a small equipment footprint. The process is designed to purify the bioactive molecules of the raw krill oil through continuous and consecutive decantations. This approach will enable improved quality control and cGMP compliance, while reducing energy consumption, waste, and raw material, in a cost-effective manner.

“We worked closely with Acasti Pharma to design and engineer a unique and innovative continuous manufacturing process for CaPre [omega-3 phospholipid],” said Yves Michon, CEO of CordenPharma Chenôve. “This process has been installed at CordenPharma Chenôve and will allow us to efficiently scale up the volume of CaPre needed for Acasti’s Phase III trial and early commercial demand.”

Source: CordenPharma

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content